PENGEMBANGAN FORMULASI TABLET LEPAS TERKENDALI ORAL MENGANDUNG EKSTRAK CANGKANG BIJI MELINJO (GNETUM GNEMON L.)

• Main Author: Tirza, Evelyn
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/51535
• Institution: Institut Teknologi Bandung

Indonesia is rich in natural resources that have the potential to be used as raw materials for medicine. One of the potential plants is melinjo. Melinjo (Gnetum gnemon L.) is incorrectly known by common people as a trigger for blood uric acid level increment. It is reported that various potential bioactive compounds are present in the shell of melinjo seeds that can be used as antihyperuricemia. Melinjo seed shells are rich in trans-resveratrol (3,5,4'-trihydroxy-trans-stilbene) and resveratrol dimer which can reduce uric acid levels. Until now, no product available derived from melinjo seed shell extract for anti-hyperuricemia due to lack of bioavailability of resveratrol dimer and trans-resveratrol short half-life (1-3 hours), and fast elimination from the body as a result of glucoronidation and sulfonation reactions into inactive substances. This study aims to develop a controlled release tablet from melinjo shell extract using a combination of hydrophobic and hydrophilic matrices, namely Eudragit RS PO and HPMC K100M, then study the in vitro release kinetics of active substance from the preparation. Controlled release of tablets was made by wet granulation method. Furthermore, evaluation of granules and tablets was carried out to obtain the optimum formula. According to the result, the F2 and F3 formulas which contained HPMC K100M matrix (20% w/w):Eudragit RS PO (20% w/w) and HPMC K100M (25% w/w):Eudragit RS PO (15% w/w) exhibited promising release profile. These two formulas therefore are potential as controlled released melinjo seed shell extract tablets with a release target for 8 hours.